Physician profile
William J Mcdaniel
NPI 1437243334
$33,173.63
in general payments reported to CMS, 2019-2025
35 companies · $3,187 in 2025
The $3,187 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $146 · 2021: $396 · 2022: $8,678 · 2023: $9,612 · 2024: $11K · 2025: $3,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $3,829 · Travel and Lodging: $90.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,638.39 |
| Food and Beverage | $3,828.93 |
| Travel and Lodging | $90.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $29,601.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $464.40 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $417.64 | 2023-2025 | |
| Amgen INC. | $268.68 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $236.18 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $236.01 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $199.60 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $190.74 | 2019-2025 | Contrave |
| Rhythm Pharmaceuticals, INC. | $154.40 | 2021-2023 | Imcivree |
| Pfizer INC. | $147.93 | 2024-2025 | |
| Inspire Medical Systems, INC. | $137.89 | 2024-2025 | Inspire |
| Dexcom, INC. | $120.35 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.50 | 2024-2025 | Jardiance |
| Vivus LLC | $85.77 | 2022-2023 | Qsymia |
| Idorsia Pharmaceuticals US INC | $76.24 | 2023-2025 | Quviviq, Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kvk-Tech, INC. | $71.64 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.43 | 2024-2025 | Caplyta |
| Esperion Therapeutics, INC. | $64.83 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $52.17 | 2025 | Veozah |
| Teleflex LLC | $50.17 | 2023-2024 | Weck, Titan Sgs |
| Kowa Pharmaceuticals America, INC. | $46.83 | 2022-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $45.69 | 2025 | |
| Dynavax Technologies Corporation | $36.65 | 2023-2024 | Heplisav-B |
| Ethicon US, LLC | $34.73 | 2023 | Echelon Endopath |
| Nestle Healthcare Nutrition INC. | $34.68 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $33.62 | 2025 | Opsumit, Uptravi |
| Corcept Therapeutics | $31.13 | 2025 | Korlym |
| Davol INC. | $28.02 | 2022 | |
| Baxter Healthcare | $27.32 | 2023 | Peri-Strips Dry |
| Abbott Laboratories | $25.39 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2025 | Xifaxan |
| Redhill Biopharma INC. | $22.01 | 2023 | Aemcolo, Talicia, Movantik |
| Sumitomo Pharma America, INC. | $17.23 | 2024 | Gemtesa |
| Integra Lifesciences Corporation | $17.16 | 2022 | |
| Merck Sharp & Dohme LLC | $14.20 | 2024 | Gardasil, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.